Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207208685> ?p ?o ?g. }
- W3207208685 endingPage "121182" @default.
- W3207208685 startingPage "121182" @default.
- W3207208685 abstract "The clinical benefit of PD-1/PD-L1 blockade immunotherapy is substantially restricted by insufficient infiltration of T lymphocytes into tumors and compromised therapeutic effects due to immune-related adverse events following systemic administration. Some chemotherapeutic agents have been reported to trigger tumor-associated T cell responses, providing a promising strategy to achieve potent immune activation in a synergistic manner with PD-1 blockade immunotherapy. In light of this, a localized chemoimmunotherapy system was developed using an anti-cancer drug-based supramolecular polymer (SP) hydrogel to re-edit the host's immune system to combat cancer. This in situ forming injectable aPD1/TT6 SP hydrogel serves as a drug-delivery depot for sustained release of bioactive camptothecin (CPT) and aPD1 into the tumor microenvironment, priming the tumor for robust infiltration of tumor-associated T cells and subsequently prompting a response to the immune checkpoint blockade. Our in vivo results demonstrate that this chemoimmunotherapy hydrogel provokes a long-term and systemic anticancer T cell immune response, which elicits tumor regression while also inhibiting tumor recurrence and potential metastasis." @default.
- W3207208685 created "2021-10-25" @default.
- W3207208685 creator A5005098364 @default.
- W3207208685 creator A5005105291 @default.
- W3207208685 creator A5008332121 @default.
- W3207208685 creator A5020200602 @default.
- W3207208685 creator A5026823543 @default.
- W3207208685 creator A5030681379 @default.
- W3207208685 creator A5044610526 @default.
- W3207208685 creator A5063084018 @default.
- W3207208685 creator A5073540788 @default.
- W3207208685 creator A5077586136 @default.
- W3207208685 creator A5078862472 @default.
- W3207208685 creator A5084854649 @default.
- W3207208685 date "2021-12-01" @default.
- W3207208685 modified "2023-10-16" @default.
- W3207208685 title "Therapeutic supramolecular tubustecan hydrogel combined with checkpoint inhibitor elicits immunity to combat cancer" @default.
- W3207208685 cites W1970274313 @default.
- W3207208685 cites W1979138479 @default.
- W3207208685 cites W1994059078 @default.
- W3207208685 cites W2013298034 @default.
- W3207208685 cites W2016612145 @default.
- W3207208685 cites W2019448830 @default.
- W3207208685 cites W2023954079 @default.
- W3207208685 cites W2027023682 @default.
- W3207208685 cites W2034365540 @default.
- W3207208685 cites W2040571524 @default.
- W3207208685 cites W2052874737 @default.
- W3207208685 cites W2060070314 @default.
- W3207208685 cites W2066671159 @default.
- W3207208685 cites W2088422531 @default.
- W3207208685 cites W2088737354 @default.
- W3207208685 cites W2112601576 @default.
- W3207208685 cites W2120426523 @default.
- W3207208685 cites W2123647020 @default.
- W3207208685 cites W2131412965 @default.
- W3207208685 cites W2142604595 @default.
- W3207208685 cites W2163326536 @default.
- W3207208685 cites W2167947388 @default.
- W3207208685 cites W2200725578 @default.
- W3207208685 cites W2213504946 @default.
- W3207208685 cites W2252550602 @default.
- W3207208685 cites W2294424925 @default.
- W3207208685 cites W2338576144 @default.
- W3207208685 cites W2343002354 @default.
- W3207208685 cites W2510686645 @default.
- W3207208685 cites W2529484692 @default.
- W3207208685 cites W2539107597 @default.
- W3207208685 cites W2568159634 @default.
- W3207208685 cites W2572376937 @default.
- W3207208685 cites W2590006252 @default.
- W3207208685 cites W2597772749 @default.
- W3207208685 cites W2619399241 @default.
- W3207208685 cites W2622573148 @default.
- W3207208685 cites W2728903533 @default.
- W3207208685 cites W2750851540 @default.
- W3207208685 cites W2768677065 @default.
- W3207208685 cites W2770810616 @default.
- W3207208685 cites W2791931250 @default.
- W3207208685 cites W2794402116 @default.
- W3207208685 cites W2802834278 @default.
- W3207208685 cites W2883713602 @default.
- W3207208685 cites W2890284346 @default.
- W3207208685 cites W2891486030 @default.
- W3207208685 cites W2902979010 @default.
- W3207208685 cites W2939112943 @default.
- W3207208685 cites W2946793129 @default.
- W3207208685 cites W2981550500 @default.
- W3207208685 cites W2997600806 @default.
- W3207208685 cites W2998744763 @default.
- W3207208685 cites W3020879277 @default.
- W3207208685 cites W3045903954 @default.
- W3207208685 cites W3047744552 @default.
- W3207208685 cites W4213080330 @default.
- W3207208685 doi "https://doi.org/10.1016/j.biomaterials.2021.121182" @default.
- W3207208685 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34688987" @default.
- W3207208685 hasPublicationYear "2021" @default.
- W3207208685 type Work @default.
- W3207208685 sameAs 3207208685 @default.
- W3207208685 citedByCount "18" @default.
- W3207208685 countsByYear W32072086852022 @default.
- W3207208685 countsByYear W32072086852023 @default.
- W3207208685 crossrefType "journal-article" @default.
- W3207208685 hasAuthorship W3207208685A5005098364 @default.
- W3207208685 hasAuthorship W3207208685A5005105291 @default.
- W3207208685 hasAuthorship W3207208685A5008332121 @default.
- W3207208685 hasAuthorship W3207208685A5020200602 @default.
- W3207208685 hasAuthorship W3207208685A5026823543 @default.
- W3207208685 hasAuthorship W3207208685A5030681379 @default.
- W3207208685 hasAuthorship W3207208685A5044610526 @default.
- W3207208685 hasAuthorship W3207208685A5063084018 @default.
- W3207208685 hasAuthorship W3207208685A5073540788 @default.
- W3207208685 hasAuthorship W3207208685A5077586136 @default.
- W3207208685 hasAuthorship W3207208685A5078862472 @default.
- W3207208685 hasAuthorship W3207208685A5084854649 @default.
- W3207208685 hasConcept C126322002 @default.
- W3207208685 hasConcept C170493617 @default.
- W3207208685 hasConcept C203014093 @default.